Search results
Showing 1651 to 1665 of 8937 results
NICE is unable to recommend the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. This is because The Medicines Company did not provide an evidence submission.
Show all sections
Sections for TA351
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA353
NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA923
In development Reference number: GID-NG10443 Expected publication date: 25 March 2026
In development Reference number: GID-IPG10318 Expected publication date: 25 March 2026
In development Reference number: GID-IPG10404 Expected publication date: 25 March 2026
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
Topic prioritisation
Topic prioritisation
Topic prioritisation
Topic prioritisation
High linear energy transfer radiation for carbon ion beam therapy
Topic prioritisation
Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia
Topic prioritisation
Percutaneous nephrolithotomy for kidney stones greater than 1.5cm
Topic prioritisation